大连市区前列腺癌流行趋势分析

高玉仁; 戴志红; 庞学成; 王梁; 刘志宇

doi:10.13201/j.issn.1001-1420.2015.05.020

大连市区前列腺癌流行趋势分析

- 大连医科大学附属第二医院泌尿外科(辽宁大连, 116011)

详细信息

通讯作者: 刘志宇,E-mail:lzydoct@163.com

中图分类号: R737.25

收稿日期: 2014-09-26

Analysis of prevalent trend of prostate cancer in Dalian city

- Department of Urology, Second Hospital of Dalian Medical University, Dalian, Liaoning, 116011, China

More Information

Corresponding author: LIU Zhiyu, E-mail: lzydoct@163.com

Received Date: 26 September 2014

摘要

摘要: 目的：研究大连市区前列腺癌的发病率、集中发病年龄及死亡人数的流行趋势，为前列腺癌的普查及诊疗提供依据。方法：对大连市区1991年以来的前列腺癌患者及其发病年龄、死亡例数进行统计研究，计算发病率及死亡粗率、标化率、年均增长率、变化百分比以及历年集中发病年龄的变化情况。结果：大连市区1991~2010年前列腺癌共发病1 208例，标准化发病率由1991年的1.7/10万逐年上升到2010年的5.1/10万；低年龄组的发病人数有明显上升趋势；大连市区2002~2012年间男性因前列腺癌死亡的人数变化不明显。结论：大连市区前列腺癌具有发病率逐年提高、集中发病年龄逐年降低、死亡人数逐步上升的趋势，前列腺癌逐渐成为威胁大连市区男性生命的最常见恶性肿瘤。
- 前列腺癌 /
- 发病率 /
- 死亡率 /
- 大连市
Abstract: Objective: To analyse the incidence, character, age of onset and mortality of prostate cancer in Dalian city so as to provide direction for diagnosis, therapy and general survey of prostate cancer.Method: The data of incidence, age of onset and mortality of prostate cancer collected in Dalian city were analyzed, and the incidence rate, age of onset, mortality rate and other indexes were calculated.Result: From 1991 to 2010, the number of prostate cancer case were 1 208. The incidence increased obviously in Dalian city from 1.7/100 000 in 1991 to 5.1/100 000 in 2010. The proportion of low age group increased significantly in the composition of the incidence over the 20 years. However, prostate cancer-associated mortality showed little change from 2002 to 2012.Conclusion: Incidence of prostate cancer in Dalian City gradually increased with years, and age at onset decreased year by year. Moreover, its mortality was rising. All these show that prostate cancer has become the most common malignant tumor threatening Dalian urban males.
- prostate cancer /
- incidence /
- mortality /
- Dalian city

HTML全文

参考文献(17)

[1]	Siegel R, Naishadham D, Jemal A.Cancer statistics, 2013[J].CA Cancer J Clin, 2013, 63(1):11-30.
[2]	Center M M, Jemal A, Lortet-Tieulent J, et al.International variation in prostate cancer incidence and mortality rates[J].Eur Urol, 2012, 61(6):1079-1092.
[3]	韩苏军, 张思维, 陈万青, 等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志, 2013, 18(4):330-334.
[4]	全国肿瘤防治研究办公室主编.中国肿瘤等级工作指导手册[M].北京:中国协和医科大学出版社, 2004:48-50.
[5]	Ferlay J, Shin H R, Bray F, et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].Int J Cancer, 2010, 127(12):2893-2917.
[6]	Siegel R, Naishadham D, Jemal A.Cancer statistics, 2012[J].CA Cancer J Clin, 2012, 62(1):10-29.
[7]	徐志兵, 王国民, 孙立安, 等.上海市前列腺癌发病情况调查分析[J].中国临床医学, 2003, 10(3):344-346.
[8]	Espey D K, Wu X C, Swan J, et al.Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives[J].Cancer, 2007, 110(10):2119-2152.
[9]	Wigle D T, Turner M C, Comes J, et al.Role of hormonal and other factors in human prostate cancer[J].J Toxieol Environ Health B CritRev, 2008, 11(34):242-259.
[10]	Silvcstri F, Bussani R, Pavletic N, et al.Neoplastic and borderline lesions of the prostate:autopsy study and epidemiological data[J].Pathol Res Pract, 1995, 191(9):908-916.
[11]	Mebane C, Gibbs T, Horm J.Current status of prostate cancer in Norlh American black mates[J].J Natl Med Assoc, 1990, 82(11):782-788.
[12]	吴英德.前列腺癌的预防研究[J].中国癌症防治杂志, 2009, 1(2):172-175.
[13]	Mullines J K, Feng Z, Trock B J, et al.The impact of anatomical radical retropubic prostatectomy on cancer control:The 30-year anniversary[J].J Urol, 2012, 188(6):2219-2224.
[14]	梁朝朝, 周骏, 张力.前列腺癌诊疗的现状与未来[J].临床泌尿外科杂志, 2014, 28(8):657-660.
[15]	王百旭, 芦志华.前列腺体积及前列腺穿刺针数对前列腺癌诊断的影响[J].现代泌尿外科杂志, 2011, 16(4):352-354.
[16]	Sanna V, Sechi M.Nanoparticle therapeutics for prostate cancer treatment[J].Nanomedicine, 2012, Suppl1:S31-36.
[17]	Demark-Wahnefried W, Schildkraut J M, Iselin C E, et al.Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina[J].Cancer, 1998, 83(2):320-330.